Bilateral pleural empyema by Enterobacter infection secondary to pancreaticopleural fistula

por Hasegawa, Koichi, Toriyama, Ayano, Nomizo, Takashi, Fukata, Hiroko, Goto, Kenichi, Nakamura, Yasukiyo, Hamada, Tatsuo, Kanda, Naoki, Kita, Hideo
Publicado 2020

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

por Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Publicado 2019

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report

por SHIMA, HIROSHI, OZASA, HIROAKI, TSUJI, TAKAHIRO, AJIMIZU, HITOMI, NOMIZO, TAKASHI, YAGI, YOSHITAKA, SAKAMORI, YUICHI, NAGAI, HIROKI, MINAMIGUCHI, SACHIKO, KIM, YOUNG HAK, MISHIMA, MICHIAKI
Publicado 2016

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

por Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Funazo, Tomoko, Yasuda, Yuto, Yoshida, Hironori, Yagi, Yoshitaka, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Publicado 2017

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

por Tsuji, Takahiro, Sakamori, Yuichi, Ozasa, Hiroaki, Yagi, Yoshitaka, Ajimizu, Hitomi, Yasuda, Yuto, Funazo, Tomoko, Nomizo, Takashi, Yoshida, Hironori, Nagai, Hiroki, Maeno, Ken, Oguri, Tetsuya, Hirai, Toyohiro, Kim, Young Hak
Publicado 2017

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

por Ogimoto, Tatsuya, Ozasa, Hiroaki, Yoshida, Hironori, Nomizo, Takashi, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Yamazoe, Masatoshi, Ajimizu, Hitomi, Tsuji, Takahiro, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Morita, Satoshi, Hirai, Toyohiro
Publicado 2023

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression

por Yasuda, Yuto, Ozasa, Hiroaki, Kim, Young Hak, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yamamoto Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Sakamori, Yuichi, Nakajima, Naoki, Menju, Toshi, Yoshizawa, Akihiko, Date, Hiroshi, Hirai, Toyohiro
Publicado 2020

Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2021

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2023

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

por Tsuji, Takahiro, Ozasa, Hiroaki, Aoki, Wataru, Aburaya, Shunsuke, Yamamoto Funazo, Tomoko, Furugaki, Koh, Yoshimura, Yasushi, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yasuda, Yuto, Nomizo, Takashi, Yoshida, Hironori, Sakamori, Yuichi, Wake, Hiroaki, Ueda, Mitsuyoshi, Kim, Young Hak, Hirai, Toyohiro
Publicado 2020